Increased midkine serum levels in pediatric embryonal tumor patients

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 10, 2009, Pages 713-717

  Lucas, Susanne ^a   Reindl, Tobias ^a   Henze, Günter ^a   Kurtz, Andreas ^a   Sakuma, Sadatoshi ^b   Driever, Pablo Hernáiz ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Cell Signals Inc   (Japan)

Author keywords

ELISA; Midkine; Solid tumor; Tumor marker

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MIDKINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADOLESCENT HEALTH; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; INJURY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHABDOMYOSARCOMA; SERODIAGNOSIS; SURGICAL TECHNIQUE; TREATMENT RESPONSE; TUMOR VOLUME;

ADOLESCENT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; NERVE GROWTH FACTORS; NEUROBLASTOMA; RHABDOMYOSARCOMA; WILMS TUMOR; YOUNG ADULT;

EID: 70349802107     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181b6db9f     Document Type: Article

References (36)

1. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in midgestation period of mouse embryogenesis. Biochem Biophys Res Commun. 1988;151:1312-1318.
2. Zhang N, Deuel TF. Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. Curr Opin Hematol. 1999;6:44-50.
3. Kaneda N, Talukder AH, Nishiyama H, et al.. Midkine, a heparin-binding growth/differentiation factor, exhibits nerve cell adhesion and guidance activity for neurite outgrowth in vitro. J Biochem (Tokyo). 1996;119:1150-1156.
4. Maeda N, Ichihara-Tanaka K, Kimura T, et al.. A receptor-like protein-tyrosine phosphatase PTPzeta/RPTPbeta binds a heparin- binding growth factor midkine. Involvement of arginine 78 of midkine in the high a.nity binding to PTPzeta. J Biol Chem. 1999;274:12474-12479.
5. Michikawa M, Kikuchi S, Muramatsu H, et al.. Retinoic acid responsive gene product, midkine, has neurotrophic functions for mouse spinal cord and dorsal root ganglion neurons in culture. J Neurosci Res. 1993;35:530-539.
6. Sato W, Kadomatsu K, Yuzawa Y, et al.. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J Immunol. 2001;167:3463-3469.
7. Horiba M, Kadomatsu K, Nakamura E, et al.. Neointima formation in a restenosis model is suppressed in midkine deficient mice. J Clin Invest. 2000;105:489-495.
8. Kurtz A, Schulte AM, Wellstein A. Pleiotrophin and midkine in normal development and tumor biology. Crit Rev Oncog. 1995;6:151-177.
9. Kadomatsu K, Hagihara M, Akhter S, et al.. Midkine induces the transformation of NIH3T3 cells. Br J Cancer. 1997;75: 354-359.
10. Kojima S, Inui T, Muramatsu H, et al.. Midkine is a heat and acid stable polypeptide capable of enhancing plasminogen activator activity and neurite outgrowth extension. Biochem Biophys Res Commun. 1995;216:574-581.
11. Muramatsu H, Muramatsu T. Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem Biophys Res Commun. 1991;177:652-658.
12. Choudhuri R, Zhang HT, Donnini S, et al.. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997;57:1814-1819.
13. Mashour GA, Driever PH, Hartmann M, et al.. Circulating growth factor levels are associated with tumorigenesis in neuro.bromatosis type 1. Clin Cancer Res. 2004;10:5677-5683.
14. Friedrich C, Holtkamp N, Cinatl J Jr, et al.. Overexpression of midkine in malignant peripheral nerve sheath tumor cells inhibits apoptosis and increases angiogenic potency. Int J Oncol. 2005;27:1433-1440.
15. Garver RI Jr, Radford DM, Donis-Keller H, et al.. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer. 1994;74:1584-1590.
16. Garver RI Jr, Chan CS, Milner PG. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol. 1993;9:463-466.
17. Shimada H, Nabeya Y, Tagawa M, et al.. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 2003;94: 628-632. (Pubitemid 36975019)
18. Aridome K, Tsutsui J, Takao S, et al.. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res. 1995;86:655-661.
19. Nakanishi T, Kadomatsu K, Okamoto T, et al.. Expression of midkine and pleiotropin in ovarian tumors. Obstet Gynecol. 1997;90:285-290.
20. O'Brien T, Cranston D, Fuggle S, et al.. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res. 1996;56:2515-2518.
21. Konishi N, Nakamura M, Nakaoka S, et al.. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology. 1999;57:253-257. (Pubitemid 29481700)
22. Mishima K, Asai A, Kadomatsu K, et al.. Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett. 1997;233:29-32. (Pubitemid 27402545)
23. Nakagawara A, Milbrandt J, Muramatsu T, et al.. Di.erential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res. 1995;55:1792-1797.
24. Tsutsui J, Kadomatsu K, Matsubara S, et al.. A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res. 1993;53:1281-1285.
25. Muramatsu H, Shirahama H, Yonezawa S, et al.. Midkine, a retinoic acid-inducible growth/differentiation factor: immunochemical evidence for the function and distribution. Dev Biol. 1993;159:392-402.
26. Ikematsu S, Yano A, Aridome K, et al.. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer. 2000;83:701-706.
27. Obata Y, Kikuchi S, Lin Y, et al.. Serum midkine concentrations and gastric cancer. Cancer Sci. 2005;96:54-56.
28. Ikematsu S, Nakagawara A, Nakamura Y, et al.. Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas. Br J Cancer. 2003;88:1522-1526.
29. Ikematsu S, Nakagawara A, Nakamura Y, et al.. Plasma midkine level is a prognostic factor for human neuroblastoma. Cancer Sci. 2008;99:2070-2074.
30. Lucas S, Henze G, Schnabel D, et al.. Serum levels of Midkine in children and adolescents without malignant disease. Pediatr Int. 2009; [Epub ahead of print], PMID: 19460128.
31. Paul S, Mitsumoto T, Asano Y, et al.. Detection of truncated midkine in Wilms' tumor by a monoclonal antibody against human recombinant truncated midkine. Cancer Lett. 2001; 163:245-251.
32. Muller HL, Oh Y, Gargosky SE, et al.. Insulin-like growth factor binding protein-3 concentrations and insulin-like growth factor binding protein-3 protease activity in sera of patients with malignant solid tumors or leukemia. Pediatr Res. 1994;35:720-724.
33. Zumkeller W, Schwander J, Mitchell CD, et al.. Insulin-like growth factor (IGF)-I, -II and IGF binding protein-2 (IGFBP- 2) in the plasma of children with Wilms' tumour. Eur J Cancer. 1993;29A:1973-1977.
34. Delahunt B, Lewis ME, Pringle KC, et al.. Serum creatine kinase levels parallel the clinical course for rhabdomyomatous Wilms tumor. Am J Clin Pathol. 2001;116:354-359.
35. Gluer S, Schelp C, Gerardy-Schahn R, et al.. Polysialylated neural cell adhesion molecule as a marker for di.erential diagnosis in pediatric tumors. J Pediatr Surg. 1998;33: 1516-1520.
36. Rebhandl W, Rami B, Turnbull J, et al.. Diagnostic value of tissue polypeptide-specific antigen (TPS) in neuroblastoma and Wilms' tumour. Br J Cancer. 1998;78:1503-1506.